Últimas noticias sobre SANUWAVE Health (NASDAQ:SNWV) Bolsa

SANUWAVE Health Inc

SANUWAVE Health

SANUWAVE Health Inc is an ultrasound and shock wave technology company using patented systems of noninvasive, high-energy, acoustic shock waves or low-intensity and non-contact ultrasound for regenerative medicine and other applications. The company's focus is regenerative medicine utilizing noninvasive, acoustic shock waves or ultrasound to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's two primary systems are UltraMIST and PACE. UltraMIST and PACE are the only two Food and Drug Administration (FDA) approved directed energy systems for wound healing.

News

SNWV

Sanuwave Health Included In Russell 2000 Index

SANUWAVE Health (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SNWV#OTC">SNWV</a>) reported quarterly losses of $(0.66) per share. This is a 54.79 percent increase over losses of $(1.46) per share from the same period last year. The company reported $9.34 million in sales this quarter. This is a 61.46 percent increase over sales of $5.79 million the same period last year.

Earnings

SANUWAVE Health Q1 EPS $(0.66) Up From $(1.46) YoY, Sales $9.34M Up From $5.79M YoY

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Guidance

SANUWAVE Health Prelim. Q1 Revenues $9.1M-$9.3M, Up 57-61% Over Q1 2024

<h3>Gainers</h3>
<ul>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock moved upwards by 66.9% to $1.11 during Monday's pre-market session. The market value of their outstanding shares is at $79.4 million. </li>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) shares rose 44.99% to $79.21. The market value of their outstanding shares is at $8.3 billion. </li>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares moved upwards by 18.6% to $0.35. The market value of their outstanding shares is at $14.4 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) shares rose 17.73% to $8.96. The market value of their outstanding shares is at $9.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares moved upwards by 15.78% to $0.85. The market value of their outstanding shares is at $2.3 million. </li>
<li>Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) stock rose 15.31% to $2.41. The market value of their outstanding shares is at $13.0 million. The company's, Q4 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) shares declined by 32.1% to $47.16 during Monday's pre-market session. The market value of their outstanding shares is at $6.0 billion. </li>
<li>PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) shares decreased by 19.8% to $0.6. The market value of their outstanding shares is at $8.2 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock declined by 19.69% to $0.02. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) shares fell 19.67% to $2.41. The market value of their outstanding shares is at $325.9 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock declined by 18.92% to $0.03. </li>
<li>SANUWAVE Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNWV#NASDAQ">SNWV</a>) stock decreased by 17.93% to $30.0. The market value of their outstanding shares is at $256.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APLM

APRE

CORT

CTOR

INNV

LGMK

PAVM

PCVX

SPRB

STSS

12 Health Care Stocks Moving In Monday's Pre-Market Session

WIIM

SANUWAVE Health shares are trading higher after the company reported a year-over-year increase in Q4 sales results.

SANUWAVE Health Q4 Sales $10.326M Up From $6.994M YoY

<h3>Companies Reporting Before The Bell</h3>
• Star Equity Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRR#NASDAQ">STRR</a>) is projected to report quarterly loss at $0.17 per share on revenue of $14.00 million. 
• Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $1.68 billion. 
• Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) is estimated to report quarterly earnings at $1.83 per share on revenue of $6.40 billion. 
• Mogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>) is likely to report quarterly loss at $0.08 per share on revenue of $12.77 million. 
• Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) is expected to report earnings for its fourth quarter. 
• Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $7.48 million. 
• InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) is estimated to report quarterly loss at $0.28 per share on revenue of $125 thousand. 
• Beasley Broadcast Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) is likely to report earnings for its fourth quarter. 
• Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $8.42 million. 
• Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) is projected to report quarterly loss at $0.37 per share on revenue of $12.79 million. 
• Bragg Gaming Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRAG#NASDAQ">BRAG</a>) is estimated to report earnings for its fourth quarter. 
• Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) is likely to report quarterly loss at $0.24 per share on revenue of $2.98 million. 
• Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) is estimated to report quarterly earnings at $2.79 per share on revenue of $3.22 billion. 
• FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) is likely to report quarterly earnings at $4.18 per share on revenue of $570.67 million. 
• Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) is likely to report quarterly earnings at $0.24 per share on revenue of $35.14 million. 
• Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $120.93 million. 
• Titan Machinery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) is estimated to report quarterly loss at $0.63 per share on revenue of $728.55 million. 
• Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) is estimated to report quarterly loss at $0.49 per share on revenue of $719.32 million. 
• Caleres (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAL#NYSE">CAL</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $646.05 million. 
• NeueHealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>) is likely to report quarterly loss at $3.99 per share on revenue of $261.80 million. 
• Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $1.75 billion. 
• Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) is expected to report quarterly earnings at $2.81 per share on revenue of $16.61 billion. 
• ARS Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) is expected to report quarterly loss at $0.12 per share on revenue of $15.90 million. 
• ZEEKR Intelligent Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) is projected to report earnings for its fourth quarter. 
• Shoe Carnival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) is estimated to report quarterly earnings at $0.44 per share on revenue of $275.92 million. 
• 111 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YI#NASDAQ">YI</a>) is expected to report earnings for its fourth quarter. 
• Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $22.61 million. 
• VEON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) is expected to report quarterly earnings at $0.77 per share on revenue of $997.00 million. 
• Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) is estimated to report quarterly loss at $0.22 per share on revenue of $56.43 million. 
• H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $798.17 million. 
• 22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) is estimated to report earnings for its fourth quarter. 
• Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) is projected to report earnings for its fourth quarter. 
• PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) is likely to report quarterly earnings at $2.56 per share on revenue of $15.68 billion. 
• Yiren Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) is likely to report earnings for its fourth quarter. 
• Neuraxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NRXS#AMEX">NRXS</a>) is likely to report earnings for its fourth quarter. 
• SPDR Select Sector Fund - Consumer Discretionary (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) is projected to report earnings for its fourth quarter. 
• Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) is expected to report earnings for its fourth quarter. 
• Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $458.69 million. 
<h3>Companies Reporting After The Bell</h3>
• Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $11.01 billion. 
• FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) is likely to report quarterly earnings at $4.54 per share on revenue of $21.89 billion. 
• Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) is expected to report quarterly earnings at $1.42 per share on revenue of $7.89 billion. 
• United States Antimony (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#AMEX">UAMY</a>) is estimated to report earnings for its fourth quarter. 
• SANUWAVE Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNWV#NASDAQ">SNWV</a>) is projected to report earnings for its fourth quarter. 
• Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) is projected to report quarterly loss at $0.48 per share on revenue of $3.30 million. 
• Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) is projected to report earnings for its fourth quarter. 
• Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) is expected to report quarterly loss at $0.05 per share on revenue of $200 thousand. 
• Intellicheck (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDN#NASDAQ">IDN</a>) is likely to report quarterly loss at $0.01 per share on revenue of $5.07 million. 
• Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) is likely to report quarterly loss at $0.11 per share on revenue of $15.68 million. 
• Flux Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $14.50 million. 
• Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) is likely to report quarterly loss at $0.85 per share on revenue of $1.75 million. 
• Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) is expected to report quarterly loss at $3.77 per share on revenue of $901 thousand. 
• Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $7.14 million. 
• Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is projected to report quarterly loss at $0.07 per share on revenue of $263.00 million. 
• Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) is expected to report quarterly earnings at $1.73 per share on revenue of $7.44 billion. 
• Scholastic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) is projected to report quarterly loss at $0.78 per share on revenue of $347.68 million. 
• Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) is projected to report quarterly loss at $0.50 per share on revenue of $1.15 million. 
• Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) is estimated to report quarterly loss at $0.66 per share on revenue of $30.93 million. 
• TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) is likely to report quarterly loss at $0.22 per share on revenue of $23.26 million. 
• Ouster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) is likely to report quarterly loss at $0.26 per share on revenue of $30.00 million. 
• Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) is projected to report quarterly loss at $0.15 per share on revenue of $17.43 million. 
• Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is expected to report quarterly loss at $0.02 per share on revenue of $62.20 million. 
• KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $645.37 million. 
• Runway Gwth Fin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $36.19 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAP

ALAR

BBGI

BRAG

BZUN

CGTX

CURV

DXLG

FLUX

GAMB

GLUE

HTHT

IFRX

LAZR

MGNX

MOGO

MSGM

NEUE

NRXS

OUST

Citigourp Global Markets 2% Protected Notes Linked To The Djia

QUBT

RKDA

RMTI

RWAY

SCHL

SCVL

SKYE

SPRY

STRR

TELA

TITN

TNON

UAMY

VALN

VEEE

VEON

VXRT

Select Sector SPDR-Consumer Discretionary

XXII

Earnings Scheduled For March 20, 2025

Sanuwave Health, Inc. (the "Company" or "Sanuwave") (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/SNWV#OTCQB">SNWV</a>), a leading provider of next-generation FDA-approved wound care products, announced today that its common stock has been approved for listing on the Nasdaq Global Market ("Nasdaq").
Trading on Nasdaq is expected to commence at the market open on March 7, 2025, with shares continuing to trade under the ticker symbol "SNWV." The Company's shares will trade on the OTCQB until trading on Nasdaq commences. Stockholders are not required to take any action as a result of the uplisting.

Sanuwave Health To Uplist To The Nasdaq Global Market; Trading On Nasdaq Is Expected To Commence At The Market Open On March 7, 2025, With Shares Continuing To Trade Under The Ticker Symbol "SNWV"

SANUWAVE Health (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SNWV#OTC">SNWV</a>) reported quarterly losses of $(6.49) per share. This is a 42.31 percent increase over losses of $(11.25) per share from the same period last year. The company reported $9.36 million in sales this quarter. This is a 88.98 percent increase over sales of $4.95 million the same period last year.

SANUWAVE Health Q3 EPS $(6.49) Up From $(9.95) YoY, Sales $9.36M Up From $4.95M YoY

Lake Street analyst Brooks O'Neil initiates coverage on SANUWAVE Health (OTC:<a class="ticker" href="/stock/SNWV#OTC">SNWV</a>) with a Buy rating and announces Price Target of $0.34.

Price Target

Initiation

Analyst Ratings

Lake Street Initiates Coverage On SANUWAVE Health with Buy Rating, Announces Price Target of $0.34

Comments

SANUWAVE Health

Noticias

Últimas noticias sobre SANUWAVE Health (NASDAQ:SNWV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL